RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.

Regulatory Focus™ > News Articles > Mutual Recognition Agreements in the EU, Canada and Other Countries

Mutual Recognition Agreements in the EU, Canada and Other Countries

Posted 01 March 2010 | By

Human and veterinary drugs are heavily regulated to ensure that they meet minimum requirements regarding quality and safety before being placed on the market. Historically, drug regulations were based on the same fundamental obligations of quality, safety and efficacy; however, regional differences in technical requirements have arisen over time. These differences often require time-consuming and expensive duplicate testing and inspections for international registrations.1

Regulatory Focus newsletters

All the biggest regulatory news and happenings.

Subscribe

Regulatory Focus™ is doing essential, non-biased journalism during this unprecedented time. We appreciate your support as we bring you the news and intelligence you need to make an impact on global healthcare.

Regulatory Focus™ provides the intelligence you need to impact global healthcare during this crisis. Thank you for your support.